Brain uptake of GSK1034702: a PET scan study, version 1

• Research type

  Research Study

• Full title

  An open label positron emission tomography (PET) study to investigate brain penetration by 11C GSK1034702 in healthy subjects

• IRAS ID

  23971

• Contact name

  Steve Warrington

• Eudract number

  2008-007450-35

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  The study medicine is an experimental treatment for mental illnesses, such as Alzheimer??s disease and schizophrenia. We hope that it will work by mimicking the effects of a substance whose levels are low in the brains of patients with these diseases.We??re doing this study to find out how much study medicine gets into the brain. We'll also test its blood levels and side effects, and study how genes (pieces of DNA) affect the way body handles or responds to it.To find out if the study medicine gets into the brain, We'll do a brain scan called a PET (positron emission tomography) scan before and after participants take a single dose of study medicine. A PET scan involves the injection of a radioactive tracer containing carbon-11. If the tracer enters the brain, the PET scan shows this. Participants will have 2 PET scans. They'll also have an MRI scan, which uses magnetism to take pictures of the brain.Up to 8 healthy men, aged 35-55 years, will take part. No-one will take dummy medicine.Participants will take up to 6 weeks to finish the study. They'll make 3 outpatient visits, and stay on the ward for 3 days and 2 nights.Healthy volunteers can??t benefit from the study medicine, but they might benefit from our screening tests, if we found an important problem.A pharmaceutical company, GlaxoSmithKline, is funding the study.The study will take place at 2 centres in London. We'll recruit healthy participants by: advertising (newspaper, radio, and websites); by word of mouth; from our volunteer database; and via our websites.

• REC name

  Scotland A REC

• REC reference

  09/IEC02/4

• Date of REC Opinion

  8 Jun 2009

• REC opinion

  Favourable Opinion